PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-2.79%
Both yoy net incomes decline, with GNPX at -56.95%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
-4.72%
Negative yoy D&A while GNPX is 19.91%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
No Data
No Data available this quarter, please select a different quarter.
-4.68%
Negative yoy SBC while GNPX is 447.96%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
284.52%
Slight usage while GNPX is negative at -158.69%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
299.08%
A yoy AP increase while GNPX is negative at -243.27%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
-348.88%
Both reduce yoy usage, with GNPX at -16.44%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
208.62%
Some yoy increase while GNPX is negative at -684653800.00%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
35.18%
Some CFO growth while GNPX is negative at -40.18%. John Neff would note a short-term liquidity lead over the competitor.
82.00%
Some CapEx rise while GNPX is negative at -908.16%. John Neff would see competitor possibly building capacity while we hold back expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
82.00%
We have mild expansions while GNPX is negative at -908.16%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.